Quick Answer
IMPACT BIOMEDICAL INC. reported Diluted EPS of $0.38 per share (loss) for fiscal year 2025.
IMPACT BIOMEDICAL INC. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.38 | +83.5% |
| 2024 | -$2.30 | -3185.7% |
| 2023 | -$0.07 | +30.0% |
| 2022 | -$0.10 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.12 | -300.0% | +89.8% |
| June 30, 2025 | -$1.18 | -1211.1% | -972.7% |
| March 31, 2025 | -$0.11 | -10.0% | -283.3% |
| September 30, 2024 | $0.06 | +400.0% | +166.7% |
| June 30, 2024 | -$0.09 | -350.0% | +10.0% |
| March 31, 2024 | -$0.10 | -900.0% | -400.0% |
| September 30, 2023 | -$0.02 | +33.3% | +0.0% |
| June 30, 2023 | -$0.02 | — | -100.0% |
- IMPACT BIOMEDICAL INC. showed an increase of +83.5% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2025 period, IMPACT BIOMEDICAL INC.’s diluted eps has declined by 280.0% (from $0.10 per share (loss) to $0.38 per share (loss)).
- The most recent figure is from IMPACT BIOMEDICAL INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: